MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ding, X.-Q.
Right arrow Articles by Miller, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ding, X.-Q.
Right arrow Articles by Miller, L. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE

Vol. 61, Issue 5, 1041-1052, May 2002

Refinement of the Conformation of a Critical Region of Charge-Charge Interaction between Cholecystokinin and Its Receptor

Xi-Qin Ding, Delia I. Pinon, Kristina E. Furse, Terry P. Lybrand, and Laurence J. Miller

Center for Basic Research in Digestive Diseases, Departments of Internal Medicine and Biochemistry/Molecular Biology, Mayo Clinic and Foundation, Rochester, Minnesota (X.-Q.D., L.J.M., D.I.P.); and Department of Chemistry and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee (K.E.F., T.P.L.)

Insight into the molecular basis of cholecystokinin (CCK) binding to its receptor has come from receptor mutagenesis and photoaffinity labeling studies, with both contributing to the current hypothesis that the acidic Tyr-sulfate-27 residue within the peptide is situated adjacent to basic Arg197 in the second loop of the receptor. Here, we refine our understanding of this region of interaction by examining a structure-activity series of these positions within both ligand and receptor and by performing three-dimensional molecular modeling of key pairs of modified ligand and receptor constructs. The important roles of Arg197 and Tyr-sulfate-27 were supported by the marked negative impact on binding and biological response with their natural partner molecule when the receptor residue was replaced by acidic Asp or Glu and when the peptide residue was replaced by basic Arg, Lys, p-amino-Phe, p-guanidino-Phe, or p-methylamino-Phe. Complementary ligand-receptor charge-exchange experiments were unable to regain the lost function. This was supported by the molecular modeling, which demonstrated that the charge-reversed double mutants could not form a good interaction without extensive rearrangement of receptor conformation. The models further predicted that R197D and R197E mutations would lead to conformational changes in the extracellular domain, and this was experimentally supported by data showing that these mutations decreased peptide agonist and antagonist binding and increased nonpeptidyl antagonist binding. These receptor constructs also had increased susceptibility to trypsin degradation relative to the wild-type receptor. In contrast, the relatively conservative R197K mutation had modest negative impact on peptide agonist binding, again consistent with the modeling demonstration of loss of a series of stabilizing inter- and intramolecular bonds. The strong correlation between predicted and experimental results support the reported refinement in the three-dimensional structure of the CCK-occupied receptor.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Conner, S. R. Hawtin, J. Simms, D. Wootten, Z. Lawson, A. C. Conner, R. A. Parslow, and M. Wheatley
Systematic Analysis of the Entire Second Extracellular Loop of the V1a Vasopressin Receptor: KEY RESIDUES, CONSERVED THROUGHOUT A G-PROTEIN-COUPLED RECEPTOR FAMILY, IDENTIFIED
J. Biol. Chem., June 15, 2007; 282(24): 17405 - 17412.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. J. Wang and Z. J. Cui
How does cholecystokinin stimulate exocrine pancreatic secretion? From birds, rodents, to humans
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R666 - R678.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. R. Hawtin, J. Simms, M. Conner, Z. Lawson, R. A. Parslow, J. Trim, A. Sheppard, and M. Wheatley
Charged Extracellular Residues, Conserved throughout a G-protein-coupled Receptor Family, Are Required for Ligand Binding, Receptor Activation, and Cell-surface Expression
J. Biol. Chem., December 15, 2006; 281(50): 38478 - 38488.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. G. Harikumar, D. I. Pinon, and L. J. Miller
Fluorescent Indicators Distributed throughout the Pharmacophore of Cholecystokinin Provide Insights into Distinct Modes of Binding and Activation of Type A and B Cholecystokinin Receptors
J. Biol. Chem., September 15, 2006; 281(37): 27072 - 27080.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. Dufresne, C. Seva, and D. Fourmy
Cholecystokinin and gastrin receptors.
Physiol Rev, July 1, 2006; 86(3): 805 - 847.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Dong, E. M. Hadac, D. I. Pinon, and L. J. Miller
Differential Spatial Approximation between Cholecystokinin Residue 30 and Receptor Residues in Active and Inactive Conformations
Mol. Pharmacol., June 1, 2005; 67(6): 1892 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. G. Harikumar and L. J. Miller
Fluorescence Resonance Energy Transfer Analysis of the Antagonist- and Partial Agonist-occupied States of the Cholecystokinin Receptor
J. Biol. Chem., May 13, 2005; 280(19): 18631 - 18635.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. G. Harikumar, J. Clain, D. I. Pinon, M. Dong, and L. J. Miller
Distinct Molecular Mechanisms for Agonist Peptide Binding to Types A and B Cholecystokinin Receptors Demonstrated Using Fluorescence Spectroscopy
J. Biol. Chem., January 14, 2005; 280(2): 1044 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
X.-Q. Ding, M. Nour, L. M. Ritter, A. F.X. Goldberg, S. J. Fliesler, and M. I. Naash
The R172W mutation in peripherin/rds causes a cone-rod dystrophy in transgenic mice
Hum. Mol. Genet., September 15, 2004; 13(18): 2075 - 2087.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. J. H. Arlander, M. Dong, X.-Q. Ding, D. I. Pinon, and L. J. Miller
Key Differences in Molecular Complexes of the Cholecystokinin Receptor with Structurally Related Peptide Agonist, Partial Agonist, and Antagonist
Mol. Pharmacol., September 1, 2004; 66(3): 545 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. G. Harikumar, D. I. Pinon, W. S. Wessels, E. S. Dawson, T. P. Lybrand, F. G. Prendergast, and L. J. Miller
Measurement of Intermolecular Distances for the Natural Agonist Peptide Docked at the Cholecystokinin Receptor Expressed in Situ Using Fluorescence Resonance Energy Transfer
Mol. Pharmacol., January 1, 2004; 65(1): 28 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. Gales, M. Poirot, J. Taillefer, B. Maigret, J. Martinez, L. Moroder, C. Escrieut, L. Pradayrol, D. Fourmy, and S. Silvente-Poirot
Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site-Directed Mutagenesis, and Structure/Affinity Studies
Mol. Pharmacol., May 1, 2003; 63(5): 973 - 982.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics